ISG15 Antikörper

Produktnummer ABIN4911217

Produktdetails anti-ISG15 Antikörper

Target: ISG15 (ISG15 Ubiquitin-Like Modifier (ISG15))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser ISG15 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF)

Kreuzreaktivität: Human

Aufreinigung: Purified by Protein G.

Immunogen: This ISG15 antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 1-165 amino acids from the N-terminal region of human ISG15.

Klon: 1C3

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IF()

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C for 12 months.

Haltbarkeit: 12 months

Details zu ISG15

Target: ISG15 (ISG15 Ubiquitin-Like Modifier (ISG15))

Andere Bezeichnung: ISG15 (ISG15 Produkte)

Synonyme: G1P2 antikoerper, IFI15 antikoerper, IP17 antikoerper, UCRP antikoerper, hUCRP antikoerper, ISG15 antikoerper, g1p2 antikoerper, si:rp71-1c23.2 antikoerper, G1p2 antikoerper, IGI15 antikoerper, Irfp antikoerper, ISG17 antikoerper, ISG17/UCRP antikoerper, ISG15 ubiquitin-like modifier antikoerper, ISG15 antikoerper, isg15 antikoerper, Isg15 antikoerper

Hintergrund:

Synonyms: G1P2, IP17, UCRP, IFI15, IMD38, hUCRP, Ubiquitin-like protein ISG15, Interferon-induced 15 kDa protein, Interferon-induced 17 kDa protein, Ubiquitin cross-reactive protein, ISG15

Background: Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity.

Gen-ID: 9636

UniProt: P05161